SEC Comment Letter 0000000000-25-002674 to TScan Therapeutics, Inc. (TCRX)
TScan Therapeutics, Inc.
Date: March 11, 2025 · CIK: 0001783328 · Accession: 0000000000-25-002674
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-285570
Letter
Re: TScan Therapeutics, Inc. Registration Statement on Form S-3 Filed March 5, 2025 File No. 333-285570 Dear Gavin MacBeath:
March 11, 2025
Gavin MacBeath Chief Executive Officer TScan Therapeutics, Inc. 830 Winter Street Waltham, MA 02451
This is to advise you that we have not reviewed and will not review your registration statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Jessica Dickerson at 202-551-8013 with any questions.
Sincerely,
Division of
Corporation Finance
Office of Life
Sciences
cc: Finnbarr Murphy, Esq.
Show Raw Text
<DOCUMENT> <TYPE>TEXT-EXTRACT <SEQUENCE>2 <FILENAME>filename2.txt <TEXT> March 11, 2025 Gavin MacBeath Chief Executive Officer TScan Therapeutics, Inc. 830 Winter Street Waltham, MA 02451 Re: TScan Therapeutics, Inc. Registration Statement on Form S-3 Filed March 5, 2025 File No. 333-285570 Dear Gavin MacBeath: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Jessica Dickerson at 202-551-8013 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc: Finnbarr Murphy, Esq. </TEXT> </DOCUMENT>